BMY

Have Bristol-Myers Squibb’s Shares Finally Found Support?

by

Image Source: kennijima By Alexander J. Poulos and Brian Nelson, CFA The pharmaceutical industry remains an area of innovation with numerous life-altering therapies brought forth to treat the many afflictions that plague us. The industry lifeblood remains the tenuous path of research and study. There is not a foolproof way to predict how a compound will respond until full clinical trials are completed and analyzed, and even successful commercialization cannot be guaranteed should a drug be approved, regardless of the time and costs invested. A later stage clinical failure, for example, could devastate a smaller company, with its equity never to recover. That’s in part why we tend to prefer larger, more diversified, entities within the pharma/biotech arena as the … Read more

There Is Milk At The Store

by

This article first appeared in the September edition of the High Yield Dividend Newsletter. For more information about this publication, please see here. “Now this is not the end. It is not even the beginning of the end. But it is, perhaps, the end of the beginning.” — Winston Churchill By Brian Nelson, CFA Very few of us could have imagined that we’d witness the bull market that began on that fateful day in March 2009 that might very well mark a generational low. In 2009, major investment banks around the globe were struggling to survive, and the fallout in the mortgage markets left the banks holding paper that nobody wanted to own, let alone buy. The global financial system … Read more

VIDEO/TRANSCRIPT: 2021 Valuentum Exclusive Call: Inflation Is Good

by

Valuentum’s President Brian Michael Nelson, CFA, explains why investors should not fear inflation, why government agencies such as the Fed and Treasury are prioritizing something other than price discovery, why the 10-year Treasury rate is a must-watch metric, and why Valuentum prefers the moaty constituents in large cap growth due to their net cash rich balance sheets, tremendous free cash flow generating potential, and secular growth tailwinds. Transcript: << Valuentum’s Best Ideas On behalf of the Valuentum team, I’d like to present to you our prepared remarks for the Valuentum Exclusive conference call for 2021. It is both an honor and a privilege to share our team’s work with you, and I personally am very grateful for your continued interest … Read more

VBI Ratings Not as Impressive As We Would Have Liked in 2022

by

Image: How the VBI rating system has ranked equities so far this year. By Brian Nelson, CFA At Valuentum, we use the Valuentum Buying Index (VBI) to source ideas into diversified simulated newsletter portfolios, and the VBI may be most applicable to the simulated Best Ideas Newsletter portfolio, where we generally like to include ideas when they register a high VBI rating and remove them when they register a low VBI rating. We always use the VBI in a portfolio setting and never by itself. But what about the Valuentum Buying Index ratings, themselves? How did they “perform” during 2022 in one of the worst years for stock market investors in history? Well, not as spectacular as we would have … Read more

Dividend Increases/Decreases for the Week of December 13

by

Below we provide a list of firms that raised their dividends during the week ending December 13. The dividend reports of covered firms on this list will be updated shortly with the new information. To access our dividend reports use the ‘Symbol’ search box in our website header. Firms Raising Their Dividends This Week                          Abbott Laboratories (ABT): now $0.59 per share quarterly dividend, was $0.55. AGNC Investment Corp. 6.5% DP SH PFD E (AGNCO): now $0.6326 per share quarterly dividend, was $0.4062. Alexandria Real Estate Equities (ARE): now $1.32 per share quarterly dividend, was $1.30. Amgen (AMGN): now $2.38 per share quarterly dividend, was $2.25. Andersons (ANDE): now $0.195 per share quarterly dividend, was $0.190. Andover Bancorp, Inc. … Read more

Bristol-Myers: Now In Play?

by

Image Source: Steve Davis Could activist investors force Bristol-Myers to break apart? Let’s walk through a potential scenario that could drive Bristol’s share price to new heights. Alexander J. Poulos We are pleased with the recent announcement of a $2 billion dollar accelerated share repurchase (ASR) program. In addition to the ASR, three new directors proposed by Jana Partners will be added to Bristol-Myers Squibb’s (BMY) board. The recent transactions by the famed activist investor have led many to believe the company is “in play” with a takeout potentially imminent. The article below will explore the potential along with our preferred solution. Oncology Franchise The crown jewel of Bristol’s product line-up remains Opdivo the programmed death receptor-1 (PD-1) blocking antibody … Read more

Top Research and Ideas You May Have Missed

by

Is Quant Value Giving Intrinsic Value Investors a Bad Name? Surely, you don’t believe Warren Buffett’s “style” is out of favor? By Brian Nelson, CFA I need to make sure that you’re aware of something very important. The media and perhaps many investment professionals define the concept of “value” as companies with low price-to-book (P/B) ratios, and the concept of “growth” as companies with high price-to-book ratios. This definition of “value” and “growth” and their corresponding returns have been magnified in writings throughout the media and across quantitative research, even in prestigious journals. Warren Buffett has been rallying against most quantitative applications and how “growth” and “value” are defined in popular media and quantitative research for decades.  Here’s one of the Oracle’s most … Read more

How to Think About Corporate Tax Reform

by

Dividend Increases/Decreases for the Week Ending December 8

by

Below we provide a list of firms that raised their dividends during the week ending December 8. The dividend reports of covered firms on this list will be updated shortly with the new information. To access our dividend reports use the ‘Symbol’ search box in our website header. Firms Raising Their Dividends This Week Agree Reality Corporation (ADC): now $0.52 per share quarterly dividend, was $0.50. Alexandria Real Estate Equities (ARE): now $0.90 per share quarterly dividend, was $0.86. Allied Properties Real Estate Investment Trust (APYRF): now CAD 0.13 per share monthly dividend, was CAD 0.1275. Axis Capital Holdings (AXS): now $0.39 per share quarterly dividend, was $0.38. Bank of Montreal (BMO): now CAD 0.93 per share quarterly dividend, was … Read more

Our Thoughts on Big Pharma’s Calendar Fourth Quarter Earnings Reports

by

Image Source: Merck & Company Inc – Fourth Quarter of 2021 IR Earnings Presentation By Callum Turcan In Alphabetical Order by Ticker: ABBV, GILD, LLY, MRK We include the Health Care Select Sector SPDR Fund ETF (XLV) in the Best Ideas Newsletter and Dividend Growth Newsletter portfolios to gain broad exposure to the health care sector. Instead of betting on one entity’s pipeline (which could be hit or miss), we like the exposure to lots and lots of “shots on goal” when it comes to the vast collective pipeline in the XLV ETF. We wrote up the calendar fourth-quarter results of the top two weightings in the XLV ETF, United Health (UNH) and Johnson & Johnson (JNJ) here and here, … Read more